Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco

Arvinas, Inc. (NASDAQ:ARVN) is among the best US stocks under $10 to invest in. XTX Topco Ltd has increased its stake in Arvinas, Inc. (NASDAQ:ARVN) by 194.2% during the first quarter, as disclosed in the company’s recent disclosure with the Securities & Exchange Commission. With the purchase of 51,658 shares, the firm now holds 78,257 shares of the company’s stock, valued at $549,000.

Arvinas, Inc. (NASDAQ:ARVN) recently achieved a milestone in its partnership with Pfizer to co-develop Vepdegestrant. The U.S. FDA is set to review the marketing application for the drug that is targeted at people with advanced or metastatic breast cancer who have previously received endocrine-based therapy. With a target action date of June 5, 2026, the solution is to address the unmet medical needs.

Considering the company’s robust balance sheet, management is confident in its resources to advance its exciting programs. Arvinas, Inc. (NASDAQ:ARVN) has prominent clinical and regulatory programs across its pipeline of PROTAC degraders, and that’s what makes it so compelling.

Arvinas, Inc. (NASDAQ:ARVN) is a Connecticut-based clinical-stage biotechnology company that engages in solutions to degrade disease-causing proteins. Founded in 2013, the company focuses on PROTAC (PROteolysis TArgeting Chimera) technology to power the body’s natural systems.

While we acknowledge the potential of ARVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.